Delicou, S., El Rassi, F., Andemariam, B., Abboud, M. R., Kanter, J., Telen, M. J., … Eisenberger, A. (2024). Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks. In Blood (Vol. 144, pp. 179–179). American Society of Hematology. https://doi.org/10.1182/blood-2024-204962

Delicou, Sophia, Fuad El Rassi, Biree Andemariam, Miguel R. Abboud, Julie Kanter, Marilyn J. Telen, Jessie Githanga, et al. “Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks.” In Blood, 144:179–179. American Society of Hematology, 2024. https://doi.org/10.1182/blood-2024-204962.

Delicou S, El Rassi F, Andemariam B, Abboud MR, Kanter J, Telen MJ, et al. Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks. In: Blood. American Society of Hematology; 2024. p. 179–179.

Delicou, Sophia, et al. “Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks.” Blood, vol. 144, no. Supplement 1, American Society of Hematology, 2024, pp. 179–179. Crossref, doi:10.1182/blood-2024-204962.

Delicou S, El Rassi F, Andemariam B, Abboud MR, Kanter J, Telen MJ, Githanga J, Inati A, Idris I, Navani S, Wu E, Eisenberger A. Etavopivat Reduces Incidence of Vaso-Occlusive Crises in Patients with Sickle Cell Disease: HIBISCUS Trial Phase 2 Results through 52 Weeks. Blood. American Society of Hematology; 2024. p. 179–179.